Literature DB >> 17854881

Omalizumab for drug allergy.

Victor Matheu, Andres Franco, Eva Perez, Marta Hernández, Yvelise Barrios.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17854881     DOI： 10.1016/j.jaci.2007.07.037

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  5 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  T cell activity in successful treatment of chronic urticaria with omalizumab.

Authors:  Inmaculada Sánchez-Machín; Javier Iglesias-Souto; Andrés Franco; Yvelise Barrios; Ruperto Gonzalez; Víctor Matheu
Journal:  Clin Mol Allergy       Date:  2011-07-26

3.  Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.

Authors:  Claudia Cavelti-Weder; Bettina Muggli; Cornelia Keller; Andrea Babians-Brunner; Anna Biason-Lauber; Marc Y Donath; Peter Schmid-Grendelmeier
Journal:  Diabetes Care       Date:  2012-06       Impact factor: 19.112

Review 4.  Human(ized) monoclonal antibodies in atopic patients - state of the art.

Authors:  Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

Review 5.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.